Bone Medical completes merger with Revenir
23 August, 2004 by Melissa TrudingerUK biotech company Bone Limited has completed its merger with Perth-based listed property management company Revenir (ASX: REV) after a successful capital raising of $2.5 million closed oversubscribed earlier in the month.
Shark antibodies may lead to new diagnostic
23 August, 2004 by Melissa TrudingerThe structure of a novel class of shark antibodies known as immunoglobulin new antibody receptors (IgNARs) isolated from wobbegong sharks (Orectolobus maculatus) has provided some clues to the evolutionary history of antibodies, and may lead to a new tool for detecting a range of human pathogens.
Acrux to deliver a September IPO
20 August, 2004 by Melissa TrudingerDrug delivery company Acrux is preparing for a late September float on the Australian Stock Exchange after filing its prospectus for an AUD$30 million IPO with the Australian Securities and Investment Commission yesterday.
Cash-poor Prima plans for agreements
20 August, 2004 by Melissa TrudingerDespite capital raisings and exercise of options totalling $7.3 million during the year, Prima Biomed (ASX: PRR) is down to a cash balance of $2.8 million after posting a net loss of $4.9 million for the 2003-2004 financial year.
Ventracor posts $16m loss
19 August, 2004 by Melissa TrudingerVentracor (ASX: VCR) yesterday posted an AUD$15.9 million net loss for the 2003-2004 financial year, up 70 per cent from last year's $9.4 million.
Australia lagging as GM industry grows
19 August, 2004 by Graeme O'NeillOne of the founders of Australia’s leading private wheat-breeding company has delivered a bleak prognosis for the commercial future of GM crops in Australia.
How to surf the GM-testing wave
18 August, 2004 by Graeme O'NeillIf there’s money in muck, there’s also moolah in mania, according to molecular geneticist Dr Roland Toder, who built the Freiburg-based biotech company GeneScan Europe into the world’s leading gene-testing company for food and food ingredients.
Biota moves US research to Australia
18 August, 2004 by Melissa TrudingerBiota (ASX: BTA) will relocate its US research operations to its new facilities in Melbourne in a bid to save costs.
Chemeq confirms details of $50m capital raising
18 August, 2004 by Melissa TrudingerChemeq (ASX: CMQ) has confirmed that its capital raising will include a placement of around AUD$10 million to institutions and sophisticated investors, as well as an underwritten rights offer of around $40 million to existing shareholders.
Proteome Systems gears up for September float
17 August, 2004 by Graeme O'NeillSydney-based proteomics pioneer Proteome Systems lodged a long-awaited prospectus for its initial public offering on the ASX with the Australian Securities and Investment Commission today.
Tissue Therapies' Upton wins award
17 August, 2004 by Melissa Trudinger\Tissue Therapies (ASX: TIS) founder and chief scientist Dr Zee Upton has won the research scientist category for the Smart Women - Smart State awards in Queensland for her work in the area of wound healing and cell culture technologies.
Canada’s agbiotech nursery gives teething lessons
16 August, 2004 by Graeme O'NeillAustralasia’s venture capital-starved biotechnology industries probably need a fairy godmother like Canada’s Foragen Technologies Management.
FDA rejects Cyberonics device, contradicts panel
13 August, 2004 by Staff WritersThe US Food and Drug Administration has refused to approve a pacemaker-like device made by Houston-based Cyberonics to treat depression rejecting the advice of its own panel of experts.
Ag genomics centre heralds toxicity discoveries
13 August, 2004 by Graeme O'NeillTwo years after it was established, the NSW Agricultural Genomics Centre is showing its mettle, announcing the discovery of several DNA markers for genes conferring tolerance to aluminium toxicity.
Xenome CEO steps down as focus moves to US
13 August, 2004 by Melissa TrudingerXenome CEO Dr Tony Evans has stepped down as the company prepares to move into a new phase of development and activity with a focus on opportunities in the US.
